GLYCOMIMETICS INC

For the period ended Dec 31, 2023. Filed Mar 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 27, 2024

CBIO$13.65+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets


	December 31,
· 2023 · · 2022
Assets · · · · · ·
Current assets:
Cash and cash equivalents		$41,792,830	$47,870,619
Prepaid expenses and other current assets		1,997,904	2,844,086
Total current assets		43,790,734	50,714,705
Prepaid research and development expenses		603,737	50,000
Operating lease right-of-use asset		767,828	751,174
Other assets		154,176	294,710
Total assets		$45,316,475	$51,810,589
Liabilities & stockholders’ equity
Current liabilities:
Accounts payable		$868,115	$970,191
Accrued expenses		5,225,557	6,992,006
Lease liabilities		741,558	918,555
Total current liabilities		6,835,230	8,880,752
Lease liabilities, net of current portion		66,844	—
Total liabilities		6,902,074	8,880,752
Stockholders’ equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022		—	—
Common stock; $0.001 par value; 100,000,000 shares authorized; 64,393,744 shares issued and outstanding at December 31, 2023; 54,377,798 shares issued and outstanding at December 31, 2022		64,394	54,378
Additional paid-in capital		494,835,219	462,461,251
Accumulated deficit		(456,485,212)	(419,585,792)
Total stockholders’ equity		38,414,401	42,929,837
Total liabilities and stockholders’ equity		$45,316,475	$51,810,589

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.